NCT04175171View on ClinicalTrials.gov

Clinical Trial of Comparative Study of GB221 Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 7, 2011

Primary Completion Date

January 8, 2012

Study Completion Date

March 8, 2012

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Coprelotamab Injection

The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.

DRUG

Trastuzumab Injection

The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.

Trial Locations (1)

6009

Linear Clinical Research Limited, Nedlands

Sponsors
All Listed Sponsors
lead

Genor Biopharma Co., Ltd.

INDUSTRY